NCT00470197View on ClinicalTrials.gov

Flavopiridol, Cytarabine, and Mitoxantrone in Treating Patients With Relapsed or Refractory Acute Leukemia

PHASE1CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

April 30, 2007

Primary Completion Date

January 31, 2011

Conditions
Adult Acute Megakaryoblastic Leukemia (M7)Adult Acute Minimally Differentiated Myeloid Leukemia (M0)Adult Acute Monoblastic Leukemia (M5a)Adult Acute Monocytic Leukemia (M5b)Adult Acute Myeloblastic Leukemia With Maturation (M2)Adult Acute Myeloblastic Leukemia Without Maturation (M1)Adult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)Adult Acute Myelomonocytic Leukemia (M4)Adult Erythroleukemia (M6a)Adult Pure Erythroid Leukemia (M6b)Malignant NeoplasmRecurrent Adult Acute Lymphoblastic LeukemiaRecurrent Adult Acute Myeloid Leukemia
Interventions
DRUG

alvocidib

Given IV

DRUG

cytarabine

Given IV

DRUG

mitoxantrone hydrochloride

Given IV

OTHER

pharmacological study

Correlative study

Trial Locations (2)

53792

University of Wisconsin Hospital and Clinics, Madison

21287-8936

Johns Hopkins University, Baltimore

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00470197 - Flavopiridol, Cytarabine, and Mitoxantrone in Treating Patients With Relapsed or Refractory Acute Leukemia | Biotech Hunter | Biotech Hunter